What is Psilera?
Headquartered in Tampa, Florida, Psilera operates at the intersection of pharmaceutical innovation and advanced computational research. The company specializes in the development of novel compounds and formulations derived from psychoactive natural products, targeting complex conditions such as mood, cognitive, and addiction disorders. With leadership drawn from the pharmaceutical and cannabis industries, Psilera leverages DEA-approved research protocols to build a proprietary drug pipeline. Their market position is defined by a patient-centric methodology that integrates high-throughput screening with next-generation computational databases, effectively bridging the gap between traditional pharmacology and emerging psychedelic science.
How much funding has Psilera raised?
Psilera has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.5M
Seed
$8.8M
Angel/Seed (2021): $2.5M, investors not publicly disclosed
Seed (2026): $8.8M, investors not publicly disclosed
Key Investors in Psilera
Undisclosed Investor
An undisclosed investor participating in the funding round, likely focused on high-growth biotechnology and pharmaceutical innovation.
Undisclosed Investor
An undisclosed investor participating in the funding round, specializing in early-stage life sciences and therapeutic development.
Undisclosed Investor
An undisclosed investor participating in the funding round, providing strategic capital to support long-term drug discovery initiatives.
What's next for Psilera?
With this major enterprise-level funding, Psilera is positioned to accelerate its clinical development programs and expand its proprietary drug pipeline. The strategic allocation of this capital will likely focus on scaling research operations, enhancing computational drug discovery capabilities, and navigating the regulatory pathways required for breakthrough therapy designations. As the company moves beyond its initial development phase, the focus will shift toward formalizing clinical trials and establishing partnerships that can facilitate the commercialization of its novel therapeutic candidates. The firm remains committed to addressing the significant unmet needs in mental health, leveraging its unique intellectual property to disrupt current treatment paradigms for chronic neurological conditions.
See full Psilera company page
